TY - JOUR
T1 - Early CNS neurodegeneration in radiologically isolated syndrome
AU - Azevedo, Christina J.
AU - Overton, Eve
AU - Khadka, Sankalpa
AU - Buckley, Jessica
AU - Liu, Shuang
AU - Sampat, Mehul
AU - Kantarci, Orhun
AU - Frenay, Christine Lebrun
AU - Siva, Aksel
AU - Okuda, Darin T.
AU - Pelletier, Daniel
N1 - Funding Information:
C.J. Azevedo served on a medical advisory board for Genzyme and received research support from the Nancy Davis Foundation. E. Overton received research support from the Foundation of the Consortium of Multiple Sclerosis Centers. S. Khadka, J. Buckley, S. Liu report no disclosures. M. Sampat is employed by Bioclinical/Synarc. O. Kantarci received speaker honoraria from Novartis; performed a grant review for the National Multiple Sclerosis Society; received research support from the European Regional Development Fund, NIH, Mayo Foundation, Hilton Foundation, Minnesota Partnership for Biotechnology and Medical Genomics, and National Multiple Sclerosis Society; has given a scientific presentation at a meeting supported by Teva Pharmaceuticals; and is on the data safety monitoring board for Takeda Global Research and Development Center, Pfizer Inc, and Janssen Alzheimer Immunotherapy. C.L. Frenay served on the scientific advisory board for Biogen Idec, Merck Serono, Genzyme, Almirall, Allergan, Teva, Sanofi, and Bayer Schering; received travel funding and/or speaker honoraria from Biogen Idec, Merck Serono, Genzyme, Almirall, Allergan, Teva, Sanofi, and Bayer Schering; and is an editorial advisory board member for Revue Neurologique. A. Siva received travel funding and/or registration coverage from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Novartis, and Teva; consulted for Biogen Idec, Novartis, and Teva; presented for Ex-cemed; and received research support from The Scientific and Technological Research Council of Turkey. D. T. Okuda received travel funding and/or speaker honoraria from Acorda Therapeutics, Genzyme, Multiple Sclerosis Association of America, MS Cure Fund, and Teva Neuroscience; has consulted for Genzyme and Teva Neuroscience; is on the speakers’ bureau for Acorda Therapeutics, Genzyme, and Teva Neuroscience; and received research support from Biogen Idec. D. Pelletier has consulted for CNS Imaging Consultant, LLC and received research support from Biogen Idec, Hoffmann-LaRoche, and NIH/National Institute of Neurological Disorders and Stroke. Go to Neurology.org/nn for full disclosure forms.
Funding Information:
This research was supported by the NIH (National Institute of Neurological Disorders and Stroke R01NS062885 to D.P.), the National Multiple Sclerosis Society (Sylvia Lawry Physician Fellowship Award FP1778-A-1 to C.J.A.), and the Race to Erase MS Foundation (14-003399 to C.J.A.).
Publisher Copyright:
© 2015 American Academy of Neurology.
PY - 2015/6
Y1 - 2015/6
N2 - Objective: Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Methods: Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age-and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm3-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Results: Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and controls, normalized left (0.0046 ± 0.0005 vs 0.0049 ± 0.0004, p = 0.006), right (0.0045 ± 0.0005 vs 0.0048 ± 0.0004, p = 0.008), and mean (0.0045 ± 0.0005 vs 0.0049 ± 0.0004, p = 0.004) thalamic volumes were significantly lower in patients with RIS (n = 21, mean age 41.9 ± 12.7 years) than in controls (n = 42, mean age 41.4 ± 11.2 years). Thalamic volumes correlated modestly with white matter lesion volumes (range: r = 20.35 to 20.47). Conclusion: Our data provide novel evidence of thalamic atrophy in RIS and are consistent with previous reports in early MS stages. Thalamic volume loss is present early in CNS demyelinating disease and should be further investigated as a metric associated with neurodegeneration.
AB - Objective: Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Methods: Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age-and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm3-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Results: Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and controls, normalized left (0.0046 ± 0.0005 vs 0.0049 ± 0.0004, p = 0.006), right (0.0045 ± 0.0005 vs 0.0048 ± 0.0004, p = 0.008), and mean (0.0045 ± 0.0005 vs 0.0049 ± 0.0004, p = 0.004) thalamic volumes were significantly lower in patients with RIS (n = 21, mean age 41.9 ± 12.7 years) than in controls (n = 42, mean age 41.4 ± 11.2 years). Thalamic volumes correlated modestly with white matter lesion volumes (range: r = 20.35 to 20.47). Conclusion: Our data provide novel evidence of thalamic atrophy in RIS and are consistent with previous reports in early MS stages. Thalamic volume loss is present early in CNS demyelinating disease and should be further investigated as a metric associated with neurodegeneration.
UR - http://www.scopus.com/inward/record.url?scp=85016962904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016962904&partnerID=8YFLogxK
U2 - 10.1212/NXI.0000000000000102
DO - 10.1212/NXI.0000000000000102
M3 - Article
AN - SCOPUS:85016962904
SN - 2332-7812
VL - 2
SP - e102
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 3
ER -